Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association: @CircAHA 🥸Congrats to authors and @AHAScience team 😱Summary 👇👇

Have you seen the new @ACCinTouch statement on Tricuspid Regurgitation yet? 👀 If not — no worries! Join us tomorrow for a live #ACCImaging webinar with the lead authors, world-class clinicians, and expert imagers as we break it all down. 💡🫀 Register now:

Thank you @imedCV and @SAC_54 for the invitation to speak in Argentina 🇦🇷 amazing conference @MonteHeart

Un placer haber compartido este #CUORE25 con el Dr Leandro Slipczuk @CardioMDPhD Del paradigma del grado de estenosis a la cuantificación de placa aterosclerotica y su fenotipo.

📢 Join us Oct 22, 2–3 PM CDT for the next ASPC CardioCore Webinar with Dr. Brittany Weber @Bweber04: Role of Inflammation in Cardiovascular Disease. Free & open to all! https://t.co/knTFmpZVUb #Cardiology #PreventiveCardiology #MedEd

Dear Faculty, Fellows, Residents and Friends Welcome to another @MonteHeart Imaging and Clinical Lectures Friday, October 10, 2025. From 12:00 pm EST – 1:00 pm EST Link: https://t.co/YsJhZrrmpj

Welcome to another @MonteHeart Imaging and Clinical Lecture Friday, October 3, 2025. From 12:00 pm EST – 1:00 pm EST Link--> https://t.co/YsJhZrrmpj

Patients may better reach LDL cholesterol goals when PCSK9 inhibitors are given in-hospital after interventions. Despite some barriers to use, "making sure that patients get the medications that are indicated by the guidelines is essential,” says lead author @CardioMDPhD.

Our meds-to-beds program helps high-risk heart patients stick with lifesaving cholesterol therapy. @CardioMDPhD explained how starting therapy before discharge gives patients the confidence to continue at home & improves long-term outcomes. Read @BeckersHR: https://t.co/WyDxlV64h6

Este año CUORE se enorgullece en contar con la participación de @CardioMDPhD @jpocardio @bplanas8 y @felipecontepomi Head Coach de @lospumas 🗓️14 de Octubre 🏨Hotel Hilton Puerto Madero 5⃣ Salones en Simultáneo Mira el programa e inscribite en https://t.co/QNiGtjEHG6

📢 No te pierdas el PreCongreso @imedCV #SAC2025 Lleno de charlas y actividades transversales a distintas áreas de la cardiología 📆14 de octubre 📍Hilton Puerto Madero

The Takeaway The ELL-ASCVD study demonstrates that access barriers, not medication efficacy, represent the primary obstacle to optimal PCSK9 inhibitor use in high-risk patients. Whatever those barriers may be, it’s important to remember that they can be removed with the right

Welcome to another @MonteHeart Imaging and Clinical Lectures Friday, September 26, 2025 From 12:00 pm EST – 1:00 pm EST Link --> https://t.co/YsJhZrqOzL

Advances in nuclear hybrid imaging: The role of SPECT/CT, PET/CT, and PET/MRI in cardiovascular diseases @almallahmo https://t.co/u3bFo7oETE

Fit-Fat Index and the risk of sudden cardiac death in Finnish men @LaukkanenJari https://t.co/DkOG9Z5tSW Ed @DrGermanMD https://t.co/rUSlDxYzyh

Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study @DLBHATTMD @ProfSNicholls @RahulAggarwalMD https://t.co/fEMwBTZVJD

Great talk by Marcus Chen at Emerging technologies for CAD imaging symposium @NIH #ACCimaging

🌟🌟Coronary artery disease: a BIG movement to change from reactive end-stage treatment to early detection and treatment: https://t.co/zmAU0Vipyl Kudos to the The Lancet Commission for actively studying the global health benefits of this paradigm shift from "ischemic" heart

Evidence is clear: the earlier and deeper the LDL-C drop post-acute coronary syndrome, the fewer cardiovascular events. Time to rethink cholesterol targets with combination therapy. Read more in #EHJ. https://t.co/vSpxHzFJlh #cardiotwitter @ESC_Journals @escardio

APOC3 inhibition: The strongest case yet for triglyceride targeting @DrMichaelShapir @CardioMDPhD https://t.co/BK8zlDveTX @WakeForest @WakeForestNews @MontefioreNYC @EinsteinMed